CYTR and MDVN release clinical data. ALXA initiates Phase 2 trial

Jan 22, 2015 No Comments by

Latest updates to the Company Pipeline Database for January 22, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALXA 2.07 AZ-002 Acute repetitive seizures Phase 2 Phase 2 initiated late Jan 2014 1/23/2015 CYTR 3.01 Aldoxorubicin Cancer – soft tissue sarcomas first line Phase 2b Overall […]

Daily News Read more

Pipeline updates and news over the previous week from 20 companies.

Aug 03, 2014 No Comments by

Pacira Pharmaceuticals, Inc.(NASDAQ: PCRX) noted that the FDA has set a PDUFA date of March 5, 2015 for the supplemental New Drug Application (sNDA) for a nerve block indication for EXPAREL. NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) said that their BAYnovation trial for viral conjunctivitis has been completed and top-line results are due in mid-August 2014. Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) maintained guidance that the pre-planned […]

Daily News Read more

NBY Phase 2b fail. CRIS CUDC-427 placed on partial hold. Upcoming data releases for IMUC FURX + updates for XLRN OCRX INCY ABIO ALXA ESPR DCTH ACAD ALNY

Nov 06, 2013 No Comments by

NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY $0.90) announced that the auriclosene Phase 2b clinical study of impetigo did not meet its primary clinical endpoint. Curis, Inc. (Nasdaq:CRIS $2.86) announced that the FDA has placed their Phase 1 study of CUDC-427 on partial clinical hold following the report of death of a patient who progressed to […]

Daily News Read more


Aug 09, 2013 No Comments

Zogenix, Inc. (Nasdaq:ZGNX $1.52) said it continues to expect that the FDA will reach a decision regarding the Zohyrdo ER New Drug Application(NDA), during the summer of 2013. NPS Pharmaceuticals, Inc. (NASDAQ: NPSP $18.10) said that it expects to submit its Biologic License Application in 4Q 2013 for Natpara for patients with hypoparathyroidism. It also plans to initiate […]

Read more

AVEO MAA won’t be pursued. CELG granted priority review. Offering details for APPY APRI ALXA + MRK OGXI LPTN MACK updates

May 24, 2013 No Comments

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) announced in a SEC filing that is was informed by its partner, Astellas Pharma Inc. that they will no longer submit a Marketing Authorization Application to the European Medicines Agency for tivozanib for the treatment of patients with advanced renal cell carcinoma. Astellas also informed AVEO that it does not […]

Read more

RPTP PDUFA date extension. NPSP receives early approval. TSPT fails Phase 2 trial. ALXA approval + SPPI news

Dec 23, 2012 No Comments

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced that FDA will require additional time to complete its review of the New Drug Application for RP103 (PROCYSBI), for the potential treatment of nephropathic cystinosis. The new PDUFA date has been extended from January 30, 2013 to April 30, 2013. NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), announced that FDA approved Gattex for subcutaneous use for the treatment of […]

Read more

30 Upcoming Catalysts – PDUFA dates, FDA Advisory meetings and Clinical data releases

Dec 01, 2012 10 Comments

30 short and long term potential catalysts as of December 1, 2012. See the links in the FDA Calendar for more details about each catalyst. Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA):  PDUFA date December 21 2012 for the Class 2 resubmssion of Staccato loxapine (ADASUVE). CHMP (EMA) decision due December 14, 2012. A.P. Pharma, Inc. (OTCBB: APPA): PDUFA Mar 27, 2013 […]

Read more

LGND FDA Approval. ALXA MAA decision due Dec 14. OXGN reverse split vote Dec 21

Nov 19, 2012 No Comments

OXiGENE, Inc. (NASDAQ: OXGN), confirmed a special meeting of stockholders will be held on December 21, 2012 at 10:00 a.m., to seek approval of a reverse stock split of its common stock, at a ratio in the range of 1:5 to 1:20. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and partner GlaxoSmithKline (NYSE: GSK) announced it received approval from the FDA for PROMACTA […]

Read more


Nov 07, 2012 No Comments

ImmunoGen, Inc. (Nasdaq: IMGN) announced that Roche has been granted priority review for trastuzumab emtansine for the treatment of people with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with Herceptin and a taxane chemotherapy. The PDUFA date is February 26, 2013. It also disclosed that its Marketing Authorization Application for trastuzumab emtansine for people […]

Read more

ALXA PDUFA date for Adasuve set for December 21 2012

Jul 05, 2012 No Comments

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that FDA accepted its resubmitted ADASUVE New Drug Application (NDA) and assigned a new PDUFA date of December 21, 2012. The company has previously received complete response letters (CRLs) in both October 2010 and a second in May 2012.  

Read more

QRX issued CRL. SUPN receives tentative FDA Approval. DVAX PDUFA set for February. ALXA files shelf. OMER offering. ATRS NDA filing due 1Q 2013 + MDVN

Jun 27, 2012 No Comments

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it received a Complete Response Letter (CRL) for MOXDUO in patients with moderate to severe acute pain. The Company has been granted a meeting with the FDA to clarify the steps required for approval. Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) received a tentative approval letter from the FDA for Trokendi XR, a once-daily extended release […]

Read more